SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

9815	Companies
196895	Keywords
127959	Articles
104711	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 10/09/2024 at 07:00, 1 year 3 months ago

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
Sanofi presents new Beyfortus data at IDWeek 2024, showcasing real-world effectiveness in protecting infants from RSV disease and hospitalization. Beyfortus doses shipped for 2024-2025 RSV season

Sanofi RSV Beyfortus Infants IDWeek
BRIEF

published on 09/27/2024 at 15:40, 1 year 4 months ago

Dupixent Approved in the US as First Biologic for COPD Patients

FDA Approval Clinical Studies COPD Dupixent Biologic Medicine
BRIEF

published on 09/27/2024 at 15:40, 1 year 4 months ago

Dupixent approuvé aux États-Unis comme premier médicament biologique pour les patients atteints de BPCO

MPoC Approbation De La FDA Études Cliniques Dupixent Médecine Biologique
PRESS RELEASE

published on 09/27/2024 at 15:35, 1 year 4 months ago

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
US FDA approves Dupixent as the first-ever biologic medicine for COPD, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. Dupixent is now leading in new-to-brand prescriptions for FDA-approved indications

FDA Approval Dupixent COPD Treatment Biologic Medicine Phase 3 Studies
PRESS RELEASE

published on 09/27/2024 at 15:35, 1 year 4 months ago

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
La FDA approuve Dupixent comme premier médicament biologique pour la BPCO aux États-Unis, offrant un nouveau traitement aux patients inadéquatement contrôlés. Résultats positifs des études BOREAS et NOTUS

FDA Traitement Études BPCO Dupixent
BRIEF

published on 09/27/2024 at 13:05, 1 year 4 months ago

Dupixent Authorized in China as First Biologic Medicine for COPD Patients

China Approval COPD Dupixent Biologic Medicine
BRIEF

published on 09/27/2024 at 13:05, 1 year 4 months ago

Dupixent autorisé en Chine comme premier médicament biologique pour les patients atteints de BPCO

Chine MPoC Approbation Dupixent Médecine Biologique
PRESS RELEASE

published on 09/27/2024 at 13:00, 1 year 4 months ago

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for COPD patients, following landmark phase 3 studies. Approval crucial for addressing COPD burden in China

China COPD Dupixent Biologic Medicine Phase 3 Studies
PRESS RELEASE

published on 09/27/2024 at 13:00, 1 year 4 months ago

Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO
Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO, réduit les exacerbations et améliore la fonction respiratoire. Approbation suite à études de phase III

Traitement Chine Approbation BPCO Dupixent
BRIEF

published on 09/21/2024 at 00:41, 1 year 4 months ago

Approbation du Sarclisa aux États-Unis pour le traitement du myélome multiple

FDA Sanofi Myélome Multiple Sarclisa Traitement De Première Ligne

Accesswire

Published on 02/06/2026 at 00:00, 24 minutes ago

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Published on 02/05/2026 at 23:15, 1 hour 9 minutes ago

Amarc Further Expands Its Toodoggone Technical Team
Published on 02/05/2026 at 23:00, 1 hour 24 minutes ago

Grounded People Announces Non-Brokered Private Placement and Strategic Review
Published on 02/05/2026 at 21:00, 3 hours 24 minutes ago

Kidoz Welcomes CloudX Innovation Driving Fairer Mobile Advertising Auctions
Published on 02/05/2026 at 18:50, 5 hours 34 minutes ago

Athena Gold Provides Exploration Update From Nevada and Ontario

View all ACCESSWIRE

EQS Group

Published on 02/05/2026 at 19:27, 4 hours 56 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 5 hours 38 minutes ago

EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 6 hours 15 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 17:55, 6 hours 29 minutes ago

Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:40, 6 hours 44 minutes ago

BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.02.26.

Les Echos

Published on 02/05/2026 at 19:24, 4 hours 59 minutes ago

Minutes of the Combined General Meeting
Published on 02/05/2026 at 19:24, 4 hours 59 minutes ago

Compte-Rendu de l’Assemblée Générale Mixte
Published on 02/05/2026 at 19:15, 5 hours 9 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 5 hours 9 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026
Published on 02/05/2026 at 19:15, 5 hours 9 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE